FLUCOPProject reference: 115672
Funded under :
Standardization and Development of Assays for Assessment of Influenza Vaccines Correlates of Protection
Total cost:EUR 13 999 165
EU contribution:EUR 6 100 000
Topic(s):IMI-JU-10-2013-01 - Immunological Assay Standardisation And Development For Use In Assessments Of Correlates Of Protection For Influenza Vaccines
Call for proposal:IMI-JU-10-2013See other projects for this call
Funding scheme:JTI-CP-IMI - Joint Technology Initiatives - Collaborative Project (IMI)
Background: Influenza viruses cause annual epidemic and occasional pandemics, both of which induce significant morbidity and mortality. Influenza infections affect all age groups but children and adults over the age of 65 are at most risk of developing severe disease.
Vaccination is the most effective approach to reduce the impact of annual influenza outbreaks and potential pandemics, however, the currently criteria of correlates of protection(CoP) show limitations in predicting protection for seasonal and pandemic vaccines.
The Haemagglutinin Inhibition(HAI) antibody titre is the most widely used CoP for seasonal influenza vaccine even if there is a lack of standardisation for conducting HAI and other serological assays and therefore results obtained from different laboratories are not comparable. This leads to the urgent need of improving international standardisation of serological assays to reduce inter laboratory variability and to generate supportive immunological assays to be used in studies aimed at developing clinically relevant surrogate markers of protection of influenza vaccines.
Objectives: The main long-term aim of the FLUCOP project is to improve and standardize the existing immunological assays and to develop new assays for the better evaluation of the CoP of influenza vaccines.
Main specific FLUCOP objectives include:
- achieve standardization of HAI and Virus Neutralization(VN) assays;
- promote the understanding and application of Cell-Mediated Immunity (CMI) and Neuraminidase (NA) assays as tools for the evaluation of influenza vaccines;
- develop selective new assays which might potentially used for future clinical trials for influenza seasonal vaccine evaluation
FLUCOP Consortium and Project Impact: The FLUCOP consortium brings together 26 groups from 7 European countries, and includes contributors from the academic, governmental, non-for-profit and pharmaceutical sectors. As a whole, the consortium has a balanced array of expertise and each group has been carefully selected to avoid overlaps in research activities and to collectively address the planned objectives. FLUCOP is expected to have a significant impact to improve and standardize the existing immunological assays and develop new assays to better evaluate influenza vaccines. This will contribute to the future clinical trial evaluation and possible establishment of correlates of protection Through a public-private collaboration FLUCOP will reach a common agreement on assays and methods to be used by all groups both from the public and private sector for testing influenza vaccines in humans. These efforts are expected to aid evolution of the regulatory guidelines and the practice of the pharmaceutical industry following the application of the methods to efficacy studies.
Project plan: To reach the proposed objectives, the FLUCOP project is composed of five focused interconnected work packages(WP).
WP1:Standardization of HAI and VN assays.
Objective: HAI and VN assays are commonly used to quantify influenza specific antibodies but they show to be highly variable between laboratories. Moreover different protocols are in use in different laboratories, which may contribute to the variability of the assays. This WP aims to improve the standardization and harmonization of these assays and also preparation and qualification of critical reagents.
Methodology: Adult and paediatric pre and post influenza vaccination serum samples will be available to consortium partners who are recognized as leading experts in serological analysis of influenza vaccine responses. A target protocol profile will be developed jointly and statistically powdered studies will be design to compare, screen and evaluate consensus protocols. Sera will be analyzed in iterative rounds of testing of the empirically selected consensus protocols and assay conditions. A final data driven consensus protocol(s) for each HAI and VN format will agreed upon, based on the results o
EU contribution: EUR 856 730
Piazza La Lizza
EU contribution: EUR 761 000
VIA BANCHI DI SOTTO 55
EU contribution: EUR 1 469 761
Quarry House, Quarry Hill
LS2 7UE Leeds
EU contribution: EUR 552 006
EU contribution: EUR 329 748
's Gravendijkwal 230
EU contribution: EUR 697 000
N-5020 P.O. Box 7800, Bergen
EU contribution: EUR 320 024
SINT PIETERSNIEUWSTRAAT 25
EU contribution: EUR 156 700
VIA FRANCESCO SFORZA
EU contribution: EUR 117 009
University Offices, Wellington Square
OX1 2JD OXFORD
EU contribution: EUR 130 000
EU contribution: EUR 150 000
IM NEUENHEIMER FELD
EU contribution: EUR 130 000
2288 GJ Rijswijk
EU contribution: EUR 250 020
VIALE REGINA ELENA
EU contribution: EUR 40 000
GU2 7XH GUILDFORD
EU contribution: EUR 100 000
EU contribution: EUR 40 002
E14 5EU Canary Wharf, London
2333 CN Leiden
1381 CP Weesp
151 85 SODERTAELJE